TGM4: an immunogenic prostate-restricted antigen

TGM4: an immunogenic prostate-restricted antigen

Background Prostate cancer is the second leading cause of cancer-related death in men in the USA; death occurs when patients progress to metastatic castration-resistant prostate cancer (CRPC). Although immunotherapy with the Food and Drug Administration‐approved vaccine sipuleucel‐T, which targets p...

Full description

Bibliographic Details
Main Authors: Laura Crowley, Charles G Drake, Ran Reshef, Pawel Muranski, Aleksandar Obradovic, Timothy O’Donnell, Uri Laserson, Tiezheng Yuan, Emmanuel S Antonarakis, Zoila A Lopez-Bujanda, Thomas R Nirschl, Rodney Macedo, Alexandros Papachristodoulou, Jelani C Zarif, Mithil K Soni, Michael C Haffner, H Benjamin Larman, Michael M Shen
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e001649.full

Internet

https://jitc.bmj.com/content/9/6/e001649.full

Similar Items